Mod­er­na seeks to dis­miss Al­ny­lam suit over Covid-19 vac­cine com­po­nent, claim­ing wrong venue

RNAi ther­a­peu­tics jug­ger­naut Al­ny­lam Phar­ma­ceu­ti­cals made a splash in March when it sued and sought mon­ey from both Pfiz­er and Mod­er­na re­gard­ing their use of Al­ny­lam’s biodegrad­able lipids, which Al­ny­lam claims have been in­te­gral to the way both com­pa­nies’ mR­NA-based Covid-19 vac­cines work.

But now, Mod­er­na lawyers are fir­ing back, telling the same Delaware dis­trict court that Al­ny­lam’s claims can on­ly pro­ceed against the US gov­ern­ment in the Court of Fed­er­al Claims be­cause of the way the com­pa­ny’s con­tract is set up with the US gov­ern­ment. The US has spent al­most $10 bil­lion on Mod­er­na’s Covid-19 vac­cine so far.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN